Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

INSIDE INFORMATION
LEGAL PROCEEDINGS

This announcement is made by Shenzhen Neptunus Interlong Bio-Technique Company Limited (the "**Company**") pursuant to Rule 17.10(2) of the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

LEGAL PROCEEDINGS

Fuzhou Neptunus Fuyao Pharmaceutical Company Limited* (福州海王福藥製藥有限公司, "**Neptunus Fuyao**"), an 80%-owned subsidiary of the Company, was served with a notice of respondence to action issued by the People's Superior Court of Beijing* (北京市高級人民法院) lately and the number of the lawsuit is (2021) Jing Min Chu No.14* ((2021) 京民初14號, the "**Lawsuit**"). The Plaintiff of the Lawsuit is Beijing Yiling Pharmaceutical Technology Development Company Limited* (北京億靈醫藥科技發展有限公司, the "**Plaintiff**"), who claimed and demanded the following from Neptunus Fuyao, the defendant of the Lawsuit (the "**Defendant**"):

1. Termination of the "Declaration, Authorization of Patent Use, Production and Sales Management Cooperation Agreement*" (《申報、專利授權使用、生產及銷售管理合作協議書》) entered into between the Plaintiff and the Defendant about the myocardial protection cardioplegic solution (HTK)* (心肌保護停跳液(赫特金)) on 9 April 2019 (the "**Agreement**").

2. Payment of RMB117.0211 million by the Defendant to the Plaintiff for the loss of market during the term of the Agreement;

   Payment of RMB35.1063 million by the Defendant to the Plaintiff as compensation for breaching of the Agreement;

Payment of the account payable of RMB743,400 by the Defendant to the Plaintiff pursuant to the Agreement;

Refund of the production deposit of RMB100,000 by the Defendant to the Plaintiff;

Bearing the attorney's fees of RMB300,000 for the Plaintiff;

The aggregated amount of the above is RMB153.2708 million.

3. Bearing of the litigation costs arising from the Lawsuit by the Defendant.

The Company is seeking legal advice in relation to the Lawsuit. Meanwhile, the Company considers that the Lawsuit does not affect the normal operations of the Company and its subsidiaries and is prudent yet optimistic to proactively deal with the Lawsuit. The Company will also publish an announcement in accordance with the GEM Listing Rules for any update on the Lawsuit.

Shareholders of the Company and potential investors should exercise caution when dealing or contemplating dealing in the shares of the Company.

By order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, PRC, 8 December 2021

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Xu Yan He; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's website at www.interlong.com.

* *For identification purpose only*